Edition:
United Kingdom

Achieve Life Sciences Inc (ACHV.OQ)

ACHV.OQ on NASDAQ Stock Exchange Capital Market

2.84USD
4:15pm BST
Change (% chg)

$0.35 (+14.06%)
Prev Close
$2.49
Open
$2.59
Day's High
$3.08
Day's Low
$2.51
Volume
55,588
Avg. Vol
114,604
52-wk High
$38.00
52-wk Low
$2.45

Latest Key Developments (Source: Significant Developments)

Achieve Life Sciences Inc QTRLY Loss Per Share $1.82
Wednesday, 8 Aug 2018 

Achieve Life Sciences Inc ::ACHIEVE REPORTS FINANCIAL RESULTS FOR SECOND QUARTER 2018 AND PROVIDES CYTISINE CLINICAL DEVELOPMENT UPDATE.ACHIEVE LIFE SCIENCES INC QTRLY LOSS PER SHARE $1.82.ACHIEVE LIFE SCIENCES - AS OF JUNE 30, CO'S CASH, CASH EQUIVALENTS, SHORT-TERM INVESTMENTS AND RESTRICTED CASH WAS $15.3 MILLION.  Full Article

Achieve Life Sciences Announces Advancement Of Cytisine Development Program Following Meeting With The FDA
Wednesday, 11 Jul 2018 

July 11 (Reuters) - Achieve Life Sciences Inc ::ACHIEVE LIFE SCIENCES ANNOUNCES ADVANCEMENT OF CYTISINE DEVELOPMENT PROGRAM FOLLOWING MEETING WITH THE FDA.ACHIEVE LIFE SCIENCES INC - ACHIEVE PLANS TO INITIATE PHASE 2B TRIAL IN Q4 OF 2018.ACHIEVE LIFE SCIENCES - FOLLOWING RESULTS FROM PHASE 2B OPTIMIZATION TRIAL, CO PLANS TO INITIATE PHASE 3 PROGRAM IN 2019.ACHIEVE LIFE SCIENCES - BASED ON FDA'S RECOMMENDATIONS, PLANS TO CONDUCT PHASE 2B OPTIMIZATION TRIAL IN ABOUT 250 SMOKERS IN U.S..  Full Article

Achieve Announces Patent Granted On Novel Formulation Of Cytisine
Monday, 7 May 2018 

May 7 (Reuters) - Achieve Life Sciences Inc ::ACHIEVE ANNOUNCES PATENT GRANTED ON NOVEL FORMULATION OF CYTISINE.  Full Article

Achieve qtrly loss per share $0.90‍​
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Achieve Life Sciences Inc ::Achieve reports financial results for third quarter 2017.Achieve Life Sciences Inc qtrly loss per share $0.90‍​.  Full Article

Achieve Life Sciences entered into exclusive supply agreement with Sopharma AD
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Sopharma Ad <3JR.BB>:Achieve Life Sciences -‍ co entered into exclusive supply agreement with Sopharma AD for manufacture of Cytisine API and finished tablets​.Achieve Life Sciences Inc - ‍exclusive license agreement provides supply of Cytisine to co for up to 20 years​.Achieve Life Sciences Inc - ‍sopharma agrees to produce CGMP-grade Cytisine for achieve's use in development and commercialization of Cytisine​.  Full Article

ACHIEVE LIFE SCIENCES COMMENCES ADVANCEMENT OF CYTISINE CLINICAL DEVELOPMENT PROGRAM
Wednesday, 4 Oct 2017 

Oct 4 (Reuters) - Achieve Life Sciences Inc ::ACHIEVE LIFE SCIENCES INC - ANNOUNCES COMMENCEMENT OF A MULTI-DOSE STUDY TO EVALUATE BOTH PK AND PD CHARACTERISTICS OF CYTISINE.ACHIEVE LIFE SCIENCES INC - ‍MULTI-DOSE PK/PD STUDY EXPECTED TO BE COMPLETED BY END OF YEAR, WITH DATA EXPECTED BY FIRST-QUARTER OF 2018​.ACHIEVE LIFE SCIENCES-‍DATA ANALYSIS ONGOING,RESULTS EXPECTED BY END OF YEAR IN STUDY FOR EVALUATING EFFECT OF FOOD ON BIOAVAILABILITY OF 3MG CYTISINE​.  Full Article

Robert Schacter reports a 16.7 percent passive stake in Achieve Life Sciences as of Aug 1
Friday, 11 Aug 2017 

Aug 11 (Reuters) - Robert Schacter :Robert Schacter reports a 16.7 percent passive stake in Achieve Life Sciences Inc as of August 1, 2017 - SEC filing‍​.  Full Article

Oncogenex says will cut about 55 pct of company's workforce
Friday, 28 Oct 2016 

Oncogenex Pharmaceuticals Inc : Oncogenex - on October 25, 2016, committed to a restructuring of a portion of company's workforce . Oncogenex Pharmaceuticals Inc - currently anticipates incurring total restructuring costs of approximately $1.4 million . Oncogenex Pharmaceuticals Inc says expects restructuring to be substantially complete in Q1 of 2017 . Oncogenex Pharmaceuticals - as part of restructuring, will eliminate 16 positions, representing approximately 55 pct of the company’s workforce .Oncogenex Pharmaceuticals- continuing to review potential impact of restructuring, is unable to estimate additional restructuring costs at this time.  Full Article

BRIEF-Achieve Qtrly Basic And Diluted Net Loss Per Share $0.24

* QTRLY BASIC AND DILUTED NET LOSS PER SHARE $0.24 Source text for Eikon: Further company coverage: